|1.||Heise, Carla: 4 articles (04/2008 - 04/2005)|
|2.||Shi, Michael: 3 articles (06/2014 - 03/2013)|
|3.||Konecny, Gottfried E: 2 articles (06/2015 - 05/2013)|
|4.||Zhou, Yongan: 2 articles (09/2014 - 09/2014)|
|5.||Li, Xinhua: 2 articles (09/2014 - 09/2014)|
|6.||Eucker, Jan: 2 articles (09/2014 - 09/2014)|
|7.||Habbel, Piet: 2 articles (09/2014 - 09/2014)|
|8.||Zang, Chuanbing: 2 articles (09/2014 - 09/2014)|
|9.||Liu, Hongyu: 2 articles (09/2014 - 09/2014)|
|10.||Scholz, Christian: 2 articles (09/2014 - 09/2014)|
11/01/2011 - "In established tumors, TKI258 (30 mg/kg/d) led to significant growth delay and improved survival in subcutaneous and orthotopic models, respectively. "
01/01/2015 - "TKI258 treatment was effective in delaying CRC tumor growth in vivo regardless of the KRAS and BRAF mutation status. "
01/01/2015 - "MTT assays, anchorage-independent colony-formation assays, and immunoblotting assays were performed to evaluate the in vitro anti-tumor effects of TKI258. "
10/01/2014 - "The effect of formulation and food consumption on the bioavailability of dovitinib (TKI258) in patients with advanced solid tumors."
07/01/2013 - "We evaluated whether dovitinib (TKI258), an inhibitor of FGFR1, FGFR2, and FGFR3, presented antitumor activity in FGFR-amplified breast cancers. "
09/01/2014 - "TKI258 may become a potent therapeutic agent, either alone or in combination with RAD001, for treatment of BCR-ABL(+) leukemia."
09/01/2014 - "This study aimed to evaluate for the first time the treatment value of the multiple tyrosine kinase inhibitor TKI258 in BCR-ABL(+) leukemia. "
09/01/2014 - "The goal of the present study was to evaluate if the multiple tyrosine kinase inhibitor (TKI) TKI258 has any treatment value for infant/childhood acute lymphoblatic leukemia (ALL), especially those ALLs bearing the mixed lineage leukemia (MLL) genes. "
09/01/2014 - "The multi-tyrosine kinase inhibitor TKI258, alone or in combination with RAD001, is effective for treatment of human leukemia with BCR-ABL translocation in vitro."
|3.||Pancreatic Neoplasms (Pancreatic Cancer)
11/01/2011 - "These data provide evidence that targeting FGFR/PDFGR/VEGFR with TKI258 may be effective in human pancreatic cancer and warrants further clinical evaluation."
11/01/2011 - "In this study, we investigated the effects of TKI258, a tyrosine kinase inhibitor to FGFR, PDGFR, and VEGFR on pancreatic cancer cell lines (HPAF-II, BxPC-3, MiaPaCa2, and L3.6pl), endothelial cells, and vascular smooth muscle cells (VSMC). "
11/01/2011 - "Results showed that treatment with TKI258 impaired activation of signaling intermediates in pancreatic cancer cells, endothelial cells, and VSMCs, even upon stimulation with FGF-1, FGF-2, VEGF-A, and PDGF-B. "
|4.||Endometrial Neoplasms (Endometrial Cancer)
06/01/2015 - "Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study."
05/01/2013 - "Here, we explore the therapeutic potential of 2 FGFR inhibitors, the multikinase inhibitor dovitinib (TKI258) and the more selective FGFR inhibitor NVP-BGJ398 for the treatment of endometrial cancer. "
05/01/2013 - "Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells."
|5.||Renal Cell Carcinoma (Grawitz Tumor)
03/01/2013 - "Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma."
06/01/2014 - "Phase II results of Dovitinib (TKI258) in patients with metastatic renal cell cancer."
06/01/2014 - "Dovitinib (TKI258) is a tyrosine kinase inhibitor (TKI) that inhibits FGF receptor (FGFR), VEGFR, and platelet-derived growth factor receptor, which are known drivers of antiangiogenic escape, angiogenesis, and tumor growth in renal cell carcinoma (RCC). "
|1.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|4.||tyrosine receptor (receptor, tyrosine)
|5.||Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)
|6.||Vascular Endothelial Growth Factor Receptors (VEGF Receptors)
|7.||Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)
|8.||Biological Markers (Surrogate Marker)
|9.||4- amino- 5- fluoro- 3- (5- (4- methylpiperazin- 1- yl)- 1H- benzimidazol- 2- yl)quinolin- 2(1H)- one
|10.||Histone Deacetylase Inhibitors
|2.||Heterologous Transplantation (Xenotransplantation)